drugset
drugset / Trial / NCT05405439

To Evaluate the Efficacy of TQB3823 Combined With Abiraterone and Prednisone in Metastatic Castration-resistant Prostate Cancer Patientsprednisone Acetate Tablets in Patients With Metastatic Castration-resistant Prostate Cancer

NCT05405439 ↗

Phase 1/2 Terminated 39 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is a phase Ib/II clinical study to explore the safety and efficacy of TQB3823 tablets combined with abiraterone acetate tablets and prednisone acetate tablets in patients with metastatic castration-resistant prostate cancer.

Timeline

Start
2022-08-25
Primary completion
2023-07-19
Completion
2023-07-19

Drugs

EvaluationDrugModalityDoseRoute
Subject TQB3823 Small molecule — —
Background Abiraterone acetate Small molecule — —
Background Prednisone Other / unclassified — —

Indications

castration-resistant prostate carcinoma